Suppr超能文献

低分子量肝素对血液透析患者脂质参数的长期影响。

Long-term effects of low molecular weight heparin on lipid parameters in hemodialysis patients.

作者信息

Elisaf M S, Bairaktari H, Germanos N, Pappas M, Koulouridis E, Papagalanis N, Siamopoulos K C

机构信息

Department of Internal Medicine, Medical School, University of Ioannina, Greece.

出版信息

Int Angiol. 1996 Sep;15(3):252-6.

PMID:8971586
Abstract

OBJECTIVE

The long-term effects of the replacement of conventional heparin by low-molecular weight heparin (LMWH) on lipid parameters were examined in a large group of hemodialysis patients.

EXPERIMENTAL DESIGN

One-year prospective investigation.

SETTING

Renal units.

PATIENTS

A total of 93 patients aged 12-63 years old receiving hemodialysis for 51 (1-172) months were studied. None of the patients had primary hyperlipidemia, diabetes mellitus, or other secondary causes of dyslipidemia.

INTERVENTIONS

In all patients administration of LMWH was introduced in doses 2500-5000 units.

MEASURES

Baseline values of lipoprotein profile prior to the intervention were compared with results obtained after 3, 6 and 12 months of LMWH.

RESULTS

During of LMWH treatment a small but statistically significant decrease of total and HDL cholesterol (from 200 +/- 45 mg/dl to 185 +/- 42 mg/dl, p < 0.01, and from 45 +/- 11 mg/dl to 42 +/- 10 mg/dl, p < 0.05, respectively), as well as Apo B (from 128 +/- 36 mg/dl to 121 +/- 35 mg/dl, p < 0.001) was noticed. Moreover, triglycerides decreased significantly (from 175 +/- 73 mg/dl to 146 +/- 62 mg/dl, p < 0.001). The beneficial effects of LMWH were more pronounced in patients with dyslipidemia (total cholesterol > 200 mg/dl, or triglycerides > 200 mg/dl) before the replacement of conventional heparin.

CONCLUSION

The long-term use of LMWH instead of conventional heparin for anticoagulation during dialysis has beneficial effects on the lipoprotein profile, especially in patients with dyslipidemia.

摘要

目的

在一大群血液透析患者中,研究低分子量肝素(LMWH)替代传统肝素对血脂参数的长期影响。

实验设计

为期一年的前瞻性研究。

研究地点

肾脏科室。

患者

共研究了93例年龄在12 - 63岁之间、接受血液透析51(1 - 172)个月的患者。所有患者均无原发性高脂血症、糖尿病或其他继发性血脂异常原因。

干预措施

所有患者均采用2500 - 5000单位剂量的LMWH进行给药。

测量指标

将干预前脂蛋白谱的基线值与LMWH治疗3、6和12个月后获得的结果进行比较。

结果

在LMWH治疗期间,总胆固醇和高密度脂蛋白胆固醇出现了轻微但具有统计学意义的下降(分别从200±45mg/dl降至185±42mg/dl,p < 0.01;从45±11mg/dl降至42±10mg/dl,p < 0.05),载脂蛋白B也出现下降(从128±36mg/dl降至121±35mg/dl,p < 0.001)。此外,甘油三酯显著下降(从175±�3mg/dl降至±462mg/dl,p < 0.001)。在替代传统肝素之前患有血脂异常(总胆固醇>200mg/dl或甘油三酯>200mg/dl)的患者中,LMWH的有益效果更为明显。

结论

在透析期间长期使用LMWH替代传统肝素进行抗凝对脂蛋白谱有有益影响,尤其是对血脂异常患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验